CN113115945A - 一种叶黄素复方微囊粉及其制备方法与应用 - Google Patents
一种叶黄素复方微囊粉及其制备方法与应用 Download PDFInfo
- Publication number
- CN113115945A CN113115945A CN202110334094.6A CN202110334094A CN113115945A CN 113115945 A CN113115945 A CN 113115945A CN 202110334094 A CN202110334094 A CN 202110334094A CN 113115945 A CN113115945 A CN 113115945A
- Authority
- CN
- China
- Prior art keywords
- lutein
- oil
- microcapsule powder
- parts
- phase component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 title claims abstract description 122
- 229960005375 lutein Drugs 0.000 title claims abstract description 119
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 title claims abstract description 119
- 235000012680 lutein Nutrition 0.000 title claims abstract description 114
- 239000001656 lutein Substances 0.000 title claims abstract description 114
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 title claims abstract description 114
- 239000003094 microcapsule Substances 0.000 title claims abstract description 62
- 239000000843 powder Substances 0.000 title claims abstract description 50
- -1 Lutein compound Chemical class 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 83
- 239000003921 oil Substances 0.000 claims abstract description 60
- 235000019198 oils Nutrition 0.000 claims abstract description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 22
- 235000019498 Walnut oil Nutrition 0.000 claims abstract description 14
- 239000008170 walnut oil Substances 0.000 claims abstract description 14
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 4
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 230000036541 health Effects 0.000 claims abstract description 3
- 239000012071 phase Substances 0.000 claims description 46
- 239000003963 antioxidant agent Substances 0.000 claims description 17
- 235000006708 antioxidants Nutrition 0.000 claims description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 15
- 230000003078 antioxidant effect Effects 0.000 claims description 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 238000004945 emulsification Methods 0.000 claims description 10
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- 240000008042 Zea mays Species 0.000 claims description 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 235000014633 carbohydrates Nutrition 0.000 claims description 7
- 235000005822 corn Nutrition 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 7
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 7
- 229960005055 sodium ascorbate Drugs 0.000 claims description 7
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical group [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 6
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 6
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 239000004368 Modified starch Substances 0.000 claims description 6
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 6
- 235000019426 modified starch Nutrition 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 229920002494 Zein Polymers 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000005019 zein Substances 0.000 claims description 5
- 229940093612 zein Drugs 0.000 claims description 5
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- 102000011632 Caseins Human genes 0.000 claims description 3
- 108010076119 Caseins Proteins 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 108010046377 Whey Proteins Proteins 0.000 claims description 3
- 102000007544 Whey Proteins Human genes 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 229940080237 sodium caseinate Drugs 0.000 claims description 3
- 229940080352 sodium stearoyl lactylate Drugs 0.000 claims description 3
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 claims description 3
- 235000021119 whey protein Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 108010055615 Zein Proteins 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 240000000950 Hippophae rhamnoides Species 0.000 claims 3
- 240000007472 Leucaena leucocephala Species 0.000 claims 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims 1
- 239000002569 water oil cream Substances 0.000 claims 1
- 241000229143 Hippophae Species 0.000 abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003960 organic solvent Substances 0.000 abstract description 5
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 abstract description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 abstract description 3
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 abstract description 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 abstract description 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 abstract description 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 150000002148 esters Chemical group 0.000 abstract description 3
- 235000012661 lycopene Nutrition 0.000 abstract description 3
- 239000001751 lycopene Substances 0.000 abstract description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 abstract description 3
- 229960004999 lycopene Drugs 0.000 abstract description 3
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 abstract description 3
- 235000010930 zeaxanthin Nutrition 0.000 abstract description 3
- 229940043269 zeaxanthin Drugs 0.000 abstract description 3
- 239000001775 zeaxanthin Substances 0.000 abstract description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 235000008210 xanthophylls Nutrition 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000003935 Hippophae Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 208000005494 xerophthalmia Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- YZNWXXJZEDHRKB-UHFFFAOYSA-N octadecyl 2-hydroxypropanoate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCCOC(=O)C(C)O YZNWXXJZEDHRKB-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
- A23L29/04—Fatty acids or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种叶黄素复方微囊粉及其制备方法与应用,所述叶黄素复方微囊粉包括以下原料:叶黄素、油相组分、水相组分和乳化剂,所述叶黄素与所述油相组分的质量比为1:1~10,所述油相组分由沙棘油和核桃油以质量比2~7:1组成。本发明通过将叶黄素溶于特定的由沙棘油和核桃油组成的油相组分中,先对叶黄素进行包裹,增加了叶黄素的稳定性,而且沙棘油中富含的玉米黄质素和番茄红素与叶黄素复配提高了叶黄素的生物利用度,完全无需使用乙醇等大量有机溶剂,也无需利用叶黄素的酯形式,同时所得微囊粉具有优异的护眼功效,在食品、药品和保健品等领域有着广泛的应用前景。
Description
技术领域
本发明涉及叶黄素相关功能食品领域,尤其涉及一种叶黄素复方微囊粉及其制备方法与应用。
背景技术
叶黄素是一种类胡萝卜素,叶黄素能够在人眼视网膜黄斑部位沉积,作为抗氧化剂或光保护剂过滤进入眼部的蓝光,对预防白内障和老龄性黄斑变性很重要。但是,叶黄素分子结构中含有多个共轭双键,易受光、热、氧气、金属离子、酸性条件和其他促氧化剂的影响发生降解或异构化,导致生物活性的损失,并且晶体形式存在的叶黄素在消化道内难以完全释放、吸收。因此,化学性质不稳定、水溶性差、口服生物利用度低严重限制了叶黄素作为功能食品的应用。
随着微囊技术的发展,人们提出将叶黄素制成微囊粉,以便于人体的吸收和利用。例如,CN101496808 A公开了一种用于视力保健的复方叶黄素微囊及其制备方法,通过花色苷色素同其他辅料成分共同包裹含有叶黄素脂质粒,提高了叶黄素的稳定性和溶解性,形成同时含有叶黄素和花色苷色素复方微囊制剂,并具有较高溶解度,大大提高了对视力保护的效果。
但是,该复方叶黄素微囊的制备过程中使用了大量有机溶剂乙醇或异丙醇,而且油相溶剂混合物需加热至170-230℃后放入水相溶剂混合物中,可能会导致不饱和脂肪酸氧化。即该方案虽然提高了叶黄素的溶解度及生物利用度,但是仍然存在着制备工艺复杂和存在安全性风险等问题。
发明内容
针对现有技术存在的问题,本发明提供一种叶黄素复方微囊粉及其制备方法与应用。
本发明采用以下技术方案:
本发明提供一种叶黄素复方微囊粉,包括以下原料:叶黄素、油相组分、水相组分和乳化剂,所述叶黄素与所述油相组分的质量比为1∶1~10,所述油相组分由沙棘油和核桃油以质量比2~7∶1组成。
本发明将叶黄素溶于特定的由沙棘油和核桃油组成的油相组分中,对该含有叶黄素的混合油脂进行包裹,增加了叶黄素的稳定性,而且沙棘油中富含的玉米黄质素和番茄红素与叶黄素复配提高了叶黄素的生物利用度,完全无需使用乙醇等大量有机溶剂,也无需利用叶黄素的酯形式。另外,沙棘油富含类胡萝卜素、生育酚类物质,其中某些成分对眼睑腺细胞具有一定抗炎和抗细胞分化作用,与叶黄素协同作用能更好地对视力有保护作用和防止眼部病变,可以阻止老年性黄斑变性发展,缓解干眼症。
在本发明的优选实施方式中,所述叶黄素与所述油相组分的质量比为1∶3~9,所述油相组分由沙棘油和核桃油以质量比2~5∶1组成。
进一步地,所述水相组分包括壁材,所述壁材为碳水化合物与蛋白的复合壁材。
优选地,所述碳水化合物与所述蛋白的质量比为2~7∶1。
微胶囊看似粉末,但其原有液态、固态或气态的本质绝无改变。微胶囊是具有一定通透性的球状小囊泡,外层为透膜或半透膜,内部为原有物质内核,所以微胶囊技术选用的壁材就尤为重要。本发明针对由叶黄素和特定油相组分组成的内容物,发现壁材选用碳水化合物与蛋白的以质量比2~7∶1组成的复合壁材时,形成的微囊较好。
优选地,所述碳水化合物为变性淀粉、麦芽糊精、固体玉米糖浆、阿拉伯胶、海藻糖、乳糖中的一种或多种,所述蛋白为明胶、酪蛋白酸钠、乳清蛋白、玉米醇溶蛋白中的一种或两种。
进一步地,所述乳化剂为单双甘油脂肪酸酯、蔗糖脂肪酸酯、琥珀酸单甘脂、硬脂酰乳酸钠中的至少两种。
进一步地,所述原料还包括水溶性抗氧化剂和油溶性抗氧化剂。
优选地,所述水溶性抗氧化剂为抗坏血酸钠和/或茶多酚。
所述油溶性抗氧化剂为抗坏血酸棕榈酸酯和/或维生素E。
在本发明的优选实施方式中,所述叶黄素复方微囊粉由以下重量份的原料组成:叶黄素10份、沙棘油及核桃油10~100份、壁材30~200份、乳化剂2~4份、水溶性抗氧化剂2~4份和油溶性抗氧化剂0.2~0.4份。
更进一步优选地,所述叶黄素复方微囊粉由以下重量份的原料组成:叶黄素10份、沙棘油15~25份、核桃油5~15份、变性淀粉35~50份、玉米醇溶蛋白20~30份、固体玉米糖浆8~15份、抗坏血酸钠3~4份、单双甘油脂肪酸酯1~2份、蔗糖脂肪酸酯1~2份、抗坏血酸棕榈酸酯0.01~0.05份和维生素E 0.2~0.3份。
本发明还提供上述叶黄素复方微囊粉的制备方法,包括将叶黄素溶于所述油相组分中完全溶解后再与水相乳化体系混合的步骤。
本发明的制备方法生产工艺简单易行且绿色环保,无需使用大量有机溶剂,即可制备得到稳定性好和生物利用度高的叶黄素复方微囊粉。
在本发明的具体实施方式中,所述叶黄素复方微囊粉的制备方法包括以下步骤:
(1)水相乳化体系制备:将水相组分、乳化剂和水溶性抗氧化剂与水混合,加热搅拌溶解制得水相乳化体系;
(2)叶黄素油相体系制备:将叶黄素和油溶性抗氧化剂加入油相组分中,混合制得叶黄素油相体系;
(3)将叶黄素油相体系加入水相乳化体系中乳化;
(4)将乳化后的溶液进行均质,制得微囊乳液;
(5)将微囊乳液进行喷雾干燥,得到所述叶黄素复方微囊粉。
其中,步骤(1)中加热搅拌温度为55~70℃;
步骤(3)中乳化时间为30~60min;
步骤(4)中均质压力为20~40MPa,均质次数为2~4次。
本发明所述叶黄素复方微囊粉质量稳定,表面油在1%以下,6个月常温放置叶黄素保留率97%以上,40℃75%条件下放置6个月叶黄素保留率90%以上;而且具有优异的护眼功效,对缓解干眼症和老年性黄斑变性等视网膜病变有积极作用,超出单独使用叶黄素、沙棘油的护眼效果,其在食品、药品和保健品中有着广泛的应用前景。既可以作为功效成分添加于各类产品中,也可以定向开发产品用于缓解眼部疾病。
本发明提供了一种叶黄素复方微囊粉及其制备方法与应用,通过将叶黄素溶于特定的由沙棘油和核桃油组成的油相组分中,对该含有叶黄素的混合油脂进行包裹,增加了叶黄素的稳定性,而且沙棘油中富含的玉米黄质素和番茄红素与叶黄素复配提高了叶黄素的生物利用度,完全无需使用乙醇等大量有机溶剂,也无需利用叶黄素的酯形式,同时所得微囊粉具有优异的护眼功效,在食品、药品和保健品等领域有着广泛的应用前景。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
若无特别说明,本发明实施例所涉及原料均可通过市售获得。
实施例1
本实施例提供一种叶黄素复方微囊粉,其制备方法如下:
(1)将10g叶黄素(含量80%)加入65g沙棘油和15g核桃油中搅拌溶解,再加入0.4g维生素E,混合均匀制得油相。
(2)将70g麦芽糊精、17g固体玉米糖浆、10g海藻糖、15g酪蛋白酸钠、0.08g茶多酚、1.5g抗坏血酸钠,2g硬脂酰乳酸钠、2g琥珀酸单甘脂加入200g纯净水中,60℃搅拌溶解30min中制得水相。
(3)将油相缓慢加入到水相中高速搅拌乳化60min,然后过高压均质机两次,均质压力为40MPa。
(4)将乳液用喷雾干燥机干燥得到叶黄素复方微囊粉,喷雾干燥条件为:进风180℃,出风温度80℃。
实施例2
本实施例提供一种叶黄素复方微囊粉,其制备方法如下:
(1)将10g叶黄素(含量80%)加入38g沙棘油和12g核桃油中搅拌溶解,再加入0.3g维生素E,0.04g抗坏血酸棕榈酸酯,混合均匀制得油相。
(2)将50g变性淀粉、20g固体玉米糖浆、10g乳糖、20g乳清分离蛋白、3.5g抗坏血酸钠、1.5g单双甘油脂肪酸酯、1.7g硬脂酰乳酸钠加入150g纯净水中,65℃搅拌溶解40min中制得水相。
(3)将油相缓慢加入到水相中高速搅拌乳化30min,然后过高压均质机两次,均质压力为30MPa。
(4)将乳液用喷雾干燥机干燥得到叶黄素复方微囊粉,喷雾干燥条件为:进风180℃,出风温度80℃。
实施例3
本实施例提供一种叶黄素复方微囊粉,其制备方法如下:
(1)将10g叶黄素(含量80%)加入20g沙棘油和10g核桃油中搅拌溶解,再加入0.2g维生素E,0.02g抗坏血酸棕榈酸酯,混合均匀制得油相。
(2)将40g变性淀粉、25g玉米醇溶蛋白、10g固体玉米糖浆、3.5g抗坏血酸钠、1.5g单双甘油脂肪酸酯、1g蔗糖脂肪酸酯加入120g纯净水中,65℃搅拌溶解30min中制得水相。
(3)将油相缓慢加入到水相中高速搅拌乳化40min,然后过高压均质机两次,均质压力为40MPa。
(4)将乳液用喷雾干燥机干燥得到叶黄素复方微囊粉,喷雾干燥条件为:进风180℃,出风温度80℃。
对比例1
本对比例提供一种叶黄素微囊粉,与实施例3的区别在于,用20g核桃油替代20g沙棘油。
对比例2
本对比例提供一种叶黄素微囊粉,与实施例3的区别在于,用10g沙棘油替代10g核桃油。
实验例1稳定性试验
表1叶黄素复方微囊粉的稳定性测试结果
表2叶黄素复方微囊粉的表面油稳定性测试结果
样品 | 0月 | 1月 | 2月 | 3月 | 6月 |
实施例1 | 0.46% | 0.48% | 0.55% | 0.78% | 1.21% |
实施例2 | 0.38% | 0.39% | 0.50 | 0.65% | 1.05% |
实施例3 | 0.30% | 0.30% | 0.42% | 0.58% | 0.95% |
注:贮存条件为40℃、RH75%放置6个月,每个月取样测试。
通过表1、2数据可以看出,相较于对比例1、2以及叶黄素单体,本发明的方案将叶黄素先溶于沙棘油和核桃油再包埋,可以最大限度地保存叶黄素物质的活性,减少外界环境因素的影响,从而提高叶黄素贮存稳定性,叶黄素在室温25℃储藏6个月后保留率为97%以上,40℃储藏6个月后保留率为91%以上,在40℃、RH75%放置6个月,表面油不超过1.21%。
实验例2生物利用度试验
选取20名年龄为50岁以上,早期AMD患者,患者随机分为两组,每组10名患者,20只眼睛,一组每日补充单一叶黄素微囊粉(对比例1提供,叶黄素含量15mg),另一组每日补充叶黄素复方微囊粉(实施例3提供,叶黄素含量15mg),跟踪随访测试6个月。在受试前及服用1个月、2个月、3个月、4个月、5个月、6个月进行检查,检查最佳矫正视力,另外也测定血清中叶黄素的浓度,结果如表3和表4所示。
表3两组早期AMD患者矫正视力比较
表4两组早期AMD患者血清中叶黄素浓度比较
从表3、4中可以看出,补充单一叶黄素微囊粉和叶黄素复方微囊粉均可对AMD早起患者视力有一定保护甚至是恢复作用,患者血液中叶黄素的浓度也有明显增加。相比于补充单一叶黄素微囊粉组,本发明实施例提供的叶黄素复方微囊粉效果更显著。
最后应说明的是:以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (10)
1.一种叶黄素复方微囊粉,包括以下原料:叶黄素、油相组分、水相组分和乳化剂,其特征在于,所述叶黄素与所述油相组分的质量比为1:1~10,所述油相组分由沙棘油和核桃油以质量比2~7:1组成。
2.根据权利要求1所述的叶黄素复方微囊粉,其特征在于,所述水相组分包括壁材,所述壁材为碳水化合物与蛋白的复合壁材;
优选地,所述碳水化合物与所述蛋白的质量比为2~7:1。
3.根据权利要求2所述的叶黄素复方微囊粉,其特征在于,所述碳水化合物为变性淀粉、麦芽糊精、固体玉米糖浆、阿拉伯胶、海藻糖、乳糖中的一种或多种,所述蛋白为明胶、酪蛋白酸钠、乳清蛋白、玉米醇溶蛋白中的一种或两种。
4.根据权利要求1~3任一项所述的叶黄素复方微囊粉,其特征在于,所述乳化剂为单双甘油脂肪酸酯、蔗糖脂肪酸酯、琥珀酸单甘脂、硬脂酰乳酸钠中的至少两种。
5.根据权利要求1~4任一项所述的叶黄素复方微囊粉,其特征在于,所述原料还包括水溶性抗氧化剂和油溶性抗氧化剂;
优选地,所述水溶性抗氧化剂为抗坏血酸钠和/或茶多酚;所述油溶性抗氧化剂为抗坏血酸棕榈酸酯和/或维生素E。
6.根据权利要求1~5任一项所述的叶黄素复方微囊粉,其特征在于,所述叶黄素复方微囊粉由以下重量份的原料组成:叶黄素10份、沙棘油及核桃油10~100份、壁材30~200份、乳化剂2~4份、水溶性抗氧化剂2~4份和油溶性抗氧化剂0.2~0.4份。
7.根据权利要求6所述的叶黄素复方微囊粉,其特征在于,所述叶黄素复方微囊粉由以下重量份的原料组成:叶黄素10份、沙棘油15~25份、核桃油5~15份、变性淀粉35~50份、玉米醇溶蛋白20~30份、固体玉米糖浆8~15份、抗坏血酸钠3~4份、单双甘油脂肪酸酯1~2份、蔗糖脂肪酸酯1~2份、抗坏血酸棕榈酸酯0.01~0.05份和维生素E 0.2~0.3份。
8.权利要求1~7任一项所述的叶黄素复方微囊粉的制备方法,其特征在于,包括将叶黄素溶于所述油相组分中完全溶解后再与水相乳化体系混合的步骤。
9.根据权利要求8所述的叶黄素复方微囊粉的制备方法,其特征在于,所述制备方法包括以下步骤:
(1)水相乳化体系制备:将水相组分、乳化剂和水溶性抗氧化剂与水混合,加热搅拌溶解制得水相乳化体系;
(2)叶黄素油相体系制备:将叶黄素和油溶性抗氧化剂加入油相组分中,混合制得叶黄素油相体系;
(3)将叶黄素油相体系加入水相乳化体系中乳化;
(4)将乳化后的溶液进行均质,制得微囊乳液;
(5)将微囊乳液进行喷雾干燥,得到所述叶黄素复方微囊粉。
10.权利要求1~7任一项所述的叶黄素复方微囊粉在食品、药品和保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110334094.6A CN113115945B (zh) | 2021-03-29 | 2021-03-29 | 一种叶黄素复方微囊粉及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110334094.6A CN113115945B (zh) | 2021-03-29 | 2021-03-29 | 一种叶黄素复方微囊粉及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113115945A true CN113115945A (zh) | 2021-07-16 |
CN113115945B CN113115945B (zh) | 2022-07-05 |
Family
ID=76774463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110334094.6A Active CN113115945B (zh) | 2021-03-29 | 2021-03-29 | 一种叶黄素复方微囊粉及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113115945B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113558241A (zh) * | 2021-07-28 | 2021-10-29 | 齐齐哈尔大学 | 一种富含叶黄素的缓解眼疲劳微乳饮品 |
CN113842434A (zh) * | 2021-11-11 | 2021-12-28 | 晨光生物科技集团股份有限公司 | 一种叶黄素微囊粉组合物及其应用 |
CN114376230A (zh) * | 2022-01-29 | 2022-04-22 | 云南农业大学 | 一种核桃油微胶囊及其制备方法 |
CN115487221A (zh) * | 2022-09-16 | 2022-12-20 | 大连工业大学 | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
CN116326779A (zh) * | 2023-04-17 | 2023-06-27 | 武汉星辰现代生物工程有限公司 | 一种叶黄素制剂及制备方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050048020A1 (en) * | 2003-07-07 | 2005-03-03 | Wille John J. | Novel topical delivery system for plant derived anti-irritants |
CN101496808A (zh) * | 2008-01-29 | 2009-08-05 | 沈阳皓天万嘉医药科技有限公司 | 一种用于视力保健的复方叶黄素微囊及其制备方法 |
CN102258499A (zh) * | 2011-08-11 | 2011-11-30 | 石河子大学医学院第一附属医院 | 叶黄素微囊的制备方法 |
CN103735532A (zh) * | 2014-01-15 | 2014-04-23 | 山东星光生物科技有限公司 | 叶黄素酯微胶囊及其制备方法 |
CN105663082A (zh) * | 2016-01-21 | 2016-06-15 | 江苏怀仁生物科技有限公司 | 一种强抗氧化性叶黄素微胶囊及其制备方法 |
CN105996040A (zh) * | 2016-05-20 | 2016-10-12 | 福建师范大学 | 一种微胶囊粉末及其制备方法 |
CN106174583A (zh) * | 2016-07-13 | 2016-12-07 | 大兴安岭超越野生浆果开发有限责任公司 | 一种沙棘油复合型食用保健品 |
CN106912623A (zh) * | 2017-03-07 | 2017-07-04 | 安阳九安农业有限责任公司 | 一种功能性油脂组合物及其制备方法 |
CN107536952A (zh) * | 2017-09-13 | 2018-01-05 | 陇南市朝华核桃产业开发有限公司 | 一种核桃油黄精软胶囊及其制备方法 |
US20180021749A1 (en) * | 2015-01-28 | 2018-01-25 | Chenguang Biotech Group Co., Ltd | Lutein microcapsule formulation and preparation method thereof |
CN111718288A (zh) * | 2020-06-29 | 2020-09-29 | 河南中大恒源生物科技股份有限公司 | 一种叶黄素酯和水溶型叶黄素酯微胶囊及其制备方法 |
-
2021
- 2021-03-29 CN CN202110334094.6A patent/CN113115945B/zh active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050048020A1 (en) * | 2003-07-07 | 2005-03-03 | Wille John J. | Novel topical delivery system for plant derived anti-irritants |
CN101496808A (zh) * | 2008-01-29 | 2009-08-05 | 沈阳皓天万嘉医药科技有限公司 | 一种用于视力保健的复方叶黄素微囊及其制备方法 |
CN102258499A (zh) * | 2011-08-11 | 2011-11-30 | 石河子大学医学院第一附属医院 | 叶黄素微囊的制备方法 |
CN103735532A (zh) * | 2014-01-15 | 2014-04-23 | 山东星光生物科技有限公司 | 叶黄素酯微胶囊及其制备方法 |
US20180021749A1 (en) * | 2015-01-28 | 2018-01-25 | Chenguang Biotech Group Co., Ltd | Lutein microcapsule formulation and preparation method thereof |
CN105663082A (zh) * | 2016-01-21 | 2016-06-15 | 江苏怀仁生物科技有限公司 | 一种强抗氧化性叶黄素微胶囊及其制备方法 |
CN105996040A (zh) * | 2016-05-20 | 2016-10-12 | 福建师范大学 | 一种微胶囊粉末及其制备方法 |
CN106174583A (zh) * | 2016-07-13 | 2016-12-07 | 大兴安岭超越野生浆果开发有限责任公司 | 一种沙棘油复合型食用保健品 |
CN106912623A (zh) * | 2017-03-07 | 2017-07-04 | 安阳九安农业有限责任公司 | 一种功能性油脂组合物及其制备方法 |
CN107536952A (zh) * | 2017-09-13 | 2018-01-05 | 陇南市朝华核桃产业开发有限公司 | 一种核桃油黄精软胶囊及其制备方法 |
CN111718288A (zh) * | 2020-06-29 | 2020-09-29 | 河南中大恒源生物科技股份有限公司 | 一种叶黄素酯和水溶型叶黄素酯微胶囊及其制备方法 |
Non-Patent Citations (2)
Title |
---|
朱式业: "植物油脂微乳制备与应用研究进展", 《中国油脂》 * |
聂斌英: "沙棘油微胶囊化研究", 《粮油食品科技》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113558241A (zh) * | 2021-07-28 | 2021-10-29 | 齐齐哈尔大学 | 一种富含叶黄素的缓解眼疲劳微乳饮品 |
CN113842434A (zh) * | 2021-11-11 | 2021-12-28 | 晨光生物科技集团股份有限公司 | 一种叶黄素微囊粉组合物及其应用 |
CN114376230A (zh) * | 2022-01-29 | 2022-04-22 | 云南农业大学 | 一种核桃油微胶囊及其制备方法 |
CN114376230B (zh) * | 2022-01-29 | 2023-04-28 | 云南农业大学 | 一种核桃油微胶囊及其制备方法 |
CN115487221A (zh) * | 2022-09-16 | 2022-12-20 | 大连工业大学 | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
CN116326779A (zh) * | 2023-04-17 | 2023-06-27 | 武汉星辰现代生物工程有限公司 | 一种叶黄素制剂及制备方法 |
CN116326779B (zh) * | 2023-04-17 | 2023-09-12 | 武汉星辰现代生物工程有限公司 | 一种叶黄素制剂及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113115945B (zh) | 2022-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113115945B (zh) | 一种叶黄素复方微囊粉及其制备方法与应用 | |
CN105613789B (zh) | 一种高脂高膳食纤维复合动植物粉末油脂、其制备方法及应用 | |
EP0347751B1 (de) | Stabile, kaltwasserdispergierbare Präparate | |
Li et al. | Improvement of fucoxanthin oral efficacy via vehicles based on gum Arabic, gelatin and alginate hydrogel: Delivery system for oral efficacy enhancement of functional food ingredients | |
CN103735532A (zh) | 叶黄素酯微胶囊及其制备方法 | |
US11793763B2 (en) | Water-soluble lutein ester microcapsules and a method of preparing the same | |
CN101904502B (zh) | 复方叶黄素软胶囊及制备方法 | |
CN105726482A (zh) | 一种叶黄素纳米脂质体及其制备方法 | |
CN103735616A (zh) | 一种用于保护视力的微囊化制剂及其制备方法 | |
CN109158061A (zh) | 一种辣椒红色素微胶囊及其制备方法与应用 | |
CN106666714B (zh) | 无糖β-胡萝卜素微胶囊及其制备方法 | |
CN109464418A (zh) | 一种维生素c维生素e软胶囊及其制备方法 | |
CN110522738A (zh) | 一种叶黄素酯微囊制剂及其制备方法和应用 | |
CN108308615A (zh) | 一种玉米肽为载体的叶黄素纳米粒的制备方法 | |
Doost et al. | Nano-lipid carriers stabilized by hydrophobically modified starch or sucrose stearate for the delivery of lutein as a nutraceutical beverage model | |
CN103381142A (zh) | 一种人参皂苷Rh1自微乳组合物及其制备方法和用途 | |
CN115444838B (zh) | 一种高生物利用度南极磷虾油叶黄素复合软胶囊及其制备方法 | |
CN108741080B (zh) | 一种微藻dha-花青素双相纳米脂质体及其制备方法 | |
CN102584662A (zh) | 一种制备水溶叶黄素的方法 | |
CN104337829B (zh) | 一瓶装脂微乳复合13种维生素冻干制剂 | |
CN113575945B (zh) | 一种纳米级高全反式类胡萝卜素干粉的制备方法 | |
CN101947214A (zh) | 一种维生素a的二次乳化、喷雾干燥法制备微胶囊方法 | |
CN110236189A (zh) | 一种保护视力的组合物及其制备方法和应用 | |
CN111567805A (zh) | 一种水溶性雨生红球藻虾青素软胶囊及其制备方法 | |
CN112515088A (zh) | 一种水分散性叶黄素酯制剂及其制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |